Skip to content

Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)

Time Course and the Significance of Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02810561
Enrollment
63
Registered
2016-06-23
Start date
2012-01-31
Completion date
2016-07-31
Last updated
2022-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraventricular Tachycardia

Keywords

Troponin

Brief summary

The goal of this study is twofold. First the investigators would like to determine the trajectory of troponin leaks; if it can be shown that the participants who have only minimal elevations of their repeat troponin universally decrease on the 3rd level then future patients may see significantly improved length of stay. Second, given conflicting results in the literature, the investigators would like to determine if elevated troponin levels correlate to later cardiovascular complications. These complications will be defined as Death, Myocardial Infarction, Cardiovascular intervention (such as coronary artery stenting or bypass). As the investigator is a single hospital system in this county it is uniquely positioned to be able to review this retrospectively.

Detailed description

The investigators therefore propose retrospectively studying participants diagnosed with Supraventricular Tachycardia who had troponin(s) checked in the ED between January 1, 2012 and May 31, 2016 to allow a minimum of a year follow-up for our combined endpoint. The investigators will record the participants troponin value(s) in addition to the age, sex, race, heart rate, creatinine value. The investigators will compare the participants with positive troponins (and hopefully participants with strongly positive troponins) with those who are negative for troponin for presence of the combined end point via chart review.

Interventions

OTHERNo Intervention

No intervention was completed with this study.

Sponsors

Corewell Health South
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Supraventricular Tachycardia with troponin elevation

Exclusion criteria

* Other cardiac arrhythmias or conditions with increased troponin

Design outcomes

Primary

MeasureTime frameDescription
Troponin-I Level6 hours after initial EKGMeasured in ng/ml

Secondary

MeasureTime frame
Death/ Need for Cardiac Stent Placement or Coronary Bypass Artery Graft6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026